Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Debiotech S.A.
NxStage’s System One has received an expanded indication to treat patients overnight at home, which the company says improves quality of life.
The company says its new needle technology means patients will only need to be pricked once during a dialysis procedure instead of twice which will reduce their discomfort while preserving vascular access.
Teleflex buys Vidacare Corp. for $262.5 million. Integra LifeSciences acquires Covidien’s Confluent Surgical product line, including the DuraSeal products, for $235 million, plus up to $30 million in milestone payments. W.L. Gore ordered to pay more than $850 million to C.R. Bard to partially resolve a long-running patent dispute. More news.
The market for insulin delivery devices is positioned to change significantly with several manufacturers gearing their products toward type 2 diabetics, who make up 90% to 95% of the diabetes patient pool in the US. These new, “pump-like” devices could offer the type 2 diabetes population better control in managing glucose levels, a solution the medical community has been seeking for a while.
- Drug Delivery
- Implantable Devices
- Surgical Equipment & Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.